PAP
AMLX icon

Persistent Asset Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Persistent Asset Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,147
Closed -$376K – 332
2025
Q4 		$376K Buy
31,147
+8,234
+36% +$112K 0.17% 157
2025
Q3 		$311K Buy
+22,913
New +$216K 0.21% 107

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Persistent Asset Partners's AMLX Position: Q1 2026 in Review

Persistent Asset Partners sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 31,147 shares — an estimated $376K sold.

Persistent Asset Partners first reported a position in AMLX in Q3 2025 and held it in 2 quarters. The position peaked at $376K in Q4 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Persistent Asset Partners reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 31,147 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $376K.
  • Persistent Asset Partners first reported a position in Amylyx Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Persistent Asset Partners's Amylyx Pharmaceuticals position peaked at $376K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.